Neurotek Unveils MOXO360™, the First Holistic Attention and Cognitive Assessment, Ahead of APA 2025 in Denver

DENVER, July 30, 2025 /PRNewswire/ -- Neurotek, a global leader in digital cognitive assessment, today announced the debut of MOXO360™, the industry's first comprehensive assessment tool designed specifically for mental health professionals. The unveiling comes just ahead of the American Psychological Association (APA) 2025 Annual Meeting in Denver, where MOXO360™ will be showcased.

A New Era in Attention and Cognitive Profiling

MOXO360™ represents a breakthrough in how attention, executive function, and learning abilities are measured and understood. Unlike traditional tests that focus solely on symptom-based diagnostics, MOXO360™ integrates clinical diagnostics with cognitive profiling to deliver a holistic, 360-degree view of an individual's attentional strengths and challenges. This unified approach empowers professionals to move beyond surface symptoms and gain actionable insights into how individuals focus, adapt, and self-regulate in real-world settings.

Key Features of MOXO360™

• Integrated Assessment: Combines clinically validated diagnostics with the first-ever cognitive attention profiler in a single, streamlined solution.
• Comprehensive Reporting: Delivers three powerful reports:
  
  • MOXO Diagnosis Report: Clinically aligned results benchmarked against a norms-based sample.
  • MOXO Profiler Report: Cognitive attentional profile compared to a global database of nearly 58,000 tests.
  • MOXO360™ Report: An integrated summary distilling key clinical and cognitive insights for targeted intervention and progress tracking.
• Advanced Data Visualizations: Interactive profile views and performance change graphs help professionals quickly identify patterns and track improvements over time.
• Real-World Relevance: Standardized distraction scores (audio, visual, combo) and executive function markers provide a nuanced understanding of cognitive performance under real-life conditions.

DESIGNED FOR MENTAL HEALTH PROFESSIONALS

MOXO360™ is tailored for:

• Clinicians: Supporting ADHD diagnosis, treatment planning, and ongoing monitoring.
• Educators: Developing evidence-based strategies for learners with attentional or self-regulatory challenges.
• Researchers: Tracking cognitive and executive function outcomes across diverse populations.
• Organizations: Informing hiring, training, and performance optimization with objective cognitive data.

Seamless Upgrade for Existing Users

Current users of MOXO Diagnosis can upgrade to MOXO360™ with a single click, retaining full access to past results and unlocking new integrated insights. Past tests from the last two years can be retroactively upgraded, enabling deeper longitudinal analysis without data loss or delays.

Setting a New Standard in Cognitive Assessment

"As mental health care shifts toward data-driven, personalized approaches, MOXO360™ sets a new industry benchmark for clarity, precision, and actionable insight," says Dr. Jacob (Yaki) Dayan, CEO of Neurotek. "With MOXO360™, professionals gain a full-spectrum view of attention and executive function - empowering them to make informed decisions that drive real-world outcomes."

MOXO360™ is now available for demonstration and pre-order at APA 2025 in Denver.

To schedule a meeting with us at APA 2025 or contact: [email protected]

About Neurotek:

Neurotek is a global leader in digital cognitive assessment. Debuted in 2014, its MOXO ADHD digital diagnosis support tool is utilized in over 50 countries and available in more than 15 languages. With over 1 million administrations in the past decade, MOXO is a trusted solution for leading healthcare systems, academic institutions, and clinics. Backed by over 100 peer-reviewed publications, Neurotek's tools empower professionals to make confident, data-driven decisions.

Neurotek's flagship MOXO360™ platform integrates clinically validated diagnostics with advanced cognitive profiling, offering a comprehensive view of cognitive wellbeing. Leveraging the industry's largest proprietary dataset, MOXO provides invaluable data for accurate diagnoses, personalized interventions, and continuous monitoring, ultimately transforming the understanding and treatment of cognitive and behavioral challenges.

Contact:
Ohad Simani
VP Sales, Neurotek
[email protected]

SOURCE Neurotek